Tyrosinase ribonucleic acid (RNA) test predicts melanoma outcome
This article was originally published in Clinica
Executive Summary
A test for tyrosinase messenger-RNA appears to predict progression in melanoma. Dr Uta Kunter of Hannover University in Germany believes tyrosinase is a marker of circulating melanoma cells and says a PCR-based test for the mRNA predicted outcome in a 64-patient study (Journal of the National Cancer Institute, May). There are currently no laboratory tests for melanoma prognosis.
You may also be interested in...
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.
Lilly Can Rest Easy As Tirzepatide Scores Phase III Sleep Apnea Win
Topline results from two studies in obstructive sleep apnea among obese adults showed efficacy crossing the 50% threshold that physicians have called clinically meaningful.
China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’
China’s public payer perceives innovative drugs in a different way from that of the country’s top drug regulator, a former senior healthcare security official with knowledge of the matter reveals. The posture has unnerved pharma companies, which have been hit by sharp price discounts.